Posts

Posted on

Lancaster Colony Appoints Elliot K. Fullen To Board Of Directors

PR Newswire

WESTERVILLE, Ohio, Feb. 24, 2021 /PRNewswire/ — Lancaster Colony Corporation (Nasdaq: LANC) announced today that its Board of Directors has appointed Elliot K. Fullen to the Company’s Board of Directors.  Mr. Fullen is currently a Senior Advisor for Arsenal Capital Partners, a leading private equity firm focusing on specialty industrial and healthcare investments.  His advisory firm, Fullen Business Consulting, works with private equity sponsors on small- to medium-size acquisitions.  Mr. Fullen’s professional experience includes the role of Vice President and General Manager for the Epoxy Specialty Products business unit of Hexion Specialty Chemicals, and he also served as Hexion’s Vice President of Strategy and Development.  An accomplished leader with over 30 years of experience, Mr. Fullen’s background encompasses global experience leading businesses and corporate strategy spanning several industries including consumer goods, specialty chemicals and healthcare packaging.     

Lancaster Colony’s Chairman, John B. Gerlach, Jr., commented, “We are excited to welcome Elliot to the Board.  His breadth of experience in strategy development and execution, mergers and acquisitions, business systems and integration, and global supply chain management will further strengthen the expertise of the Board in these areas.  We look forward to working with Elliot and leveraging his strong and diverse skill set to help grow our business and serve our stakeholders in the years ahead.”

Mr. Fullen is currently a Board Member for Airnov Healthcare Packaging, a leading global manufacturer of packaging solutions to the pharmaceutical, nutraceutical and diagnostic markets.  Mr. Fullen graduated from Northwestern University with a B.S. in Industrial Engineering / Management Science and was also captain of the Northwestern University basketball team.  He completed his M.B.A at Purdue University’s Krannert Graduate School of Management.

About the Company

Lancaster Colony Corporation is a manufacturer and marketer of specialty food products for the retail and foodservice channels.

Forward-Looking Statements

We desire to take advantage of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). This news release contains various “forward-looking statements” within the meaning of the PSLRA and other applicable securities laws. Such statements can be identified by the use of the forward-looking words “anticipate,” “estimate,” “project,” “believe,” “intend,” “plan,” “expect,” “hope” or similar words. These statements discuss future expectations; contain projections regarding future developments, operations or financial conditions; or state other forward-looking information. Such statements are based upon assumptions and assessments made by us in light of our experience and perception of historical trends, current conditions, expected future developments; and other factors we believe to be appropriate. These forward-looking statements involve numerous risks and uncertainties, including, without limitation, the various risks inherent in the Company’s business as set forth in periodic reports filed with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.   

Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update such forward-looking statements, except as required by law. Management believes these forward-looking statements to be reasonable; however, you should not place undue reliance on such statements that are based on current expectations.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/lancaster-colony-appoints-elliot-k-fullen-to-board-of-directors-301234859.html

SOURCE Lancaster Colony Corporation

Posted on

AMG Announces Changes to the Composition of the Supervisory Board and Nominates Its CEO and COO for Reappointment When Their Current Terms End in May 2021


Amsterdam,


24 February 2021


(Regulated Information)

— The Supervisory Board of AMG Advanced Metallurgical Group N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) resolved during its meeting on February 24, 2021 to propose to the General Meeting of Shareholders to nominate for reappointment Dr. Heinz Schimmelbusch and Mr. Eric Jackson for additional terms of two and four years, respectively, when their current terms expire in 2021.


Supervisory Board Composition

At the Annual General Meeting (“AGM”) in May 2021, Mr. Willem van Hassel, Vice Chairman, will have served four years on the Supervisory Board when his current term ends. On that occasion, Mr. Herb Depp, Chair of the Remuneration Committee, will have served eight years on the Supervisory Board when his current term ends. The Board is very pleased that both gentlemen have agreed to continue to serve on the Supervisory Board. The Supervisory Board will nominate Mr. van Hassel and Mr. Depp for reappointment by the General Meeting Shareholders on May 6 of this year as independent members of the Supervisory Board for terms of respectively four years (Mr. van Hassel) and two years (Mr. Depp).

Mr. Frank Löhner has indicated that he wishes to step down after the AGM on May 6 of this year due to other pressing engagements, having served three years on the Supervisory Board. The Supervisory Board respects and accepts with regret the decision of Mr. Löhner and thanks him for his valuable insights and contributions and wishes him well in his future endeavors. Given the retirement of Mr. Löhner, the Supervisory Board is very pleased to nominate Mr. Warmolt Prins for appointment by the General Meeting of Shareholders as a Supervisory Board member with effect as of May 6, 2021. Mr. Prins, who has Dutch nationality, is a chartered accountant and former partner of EY Accountants and served as external auditor (on behalf of EY) of AMG from 2010 through 2015. Mr. Prins also brings highly relevant industry experience.


Management Board Composition

The terms of both the CEO and COO (Dr. Heinz Schimmelbusch and Mr. Eric Jackson, respectively) will end in May 2021. As extensively explained in the 2017 Annual Report and at the 2018 Annual Meeting, the Supervisory Board had concluded that it was of the utmost importance that AMG secure the leadership of Dr. Heinz Schimmelbusch for the coming years as CEO and Chairman of the Management Board, given the transformational changes that had been initiated by the Company by implementing the Company’s long-term strategy.

Now, in 2021, AMG finds itself still in the midst of the COVID-19 pandemic that has shaken the world and its global economy in unprecedented ways. The Selection & Appointment Committee has held extensive discussions with its fellow board members and the Management Board about the leadership of the Company and the entirely unforeseen and dramatic impact of the COVID-19 pandemic that began in early 2020 and is expected to continue to affect AMG’s business operations and prospects in 2021 and 2022.

The committee is extremely pleased that both Dr. Schimmelbusch and Mr. Jackson have agreed to be available for extensions of their terms on the Management Board, if and when appointed, for periods of two and four years, respectively, in order to drive the strategic agenda of the Company and prepare the Company in the best possible way for the post-pandemic economy.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

This press release contains regulated information as defined in the Dutch Financial Markets Supervision Act (Wet op het financieel toezicht).

About AMG

AMG is a global critical materials company at the forefront of CO2 reduction trends. AMG produces highly engineered specialty metals and mineral products and provides related vacuum furnace systems and services to the transportation, infrastructure, energy, and specialty metals & chemicals end markets.

AMG Clean Energy Materials combines our recycling and mining operations producing materials for infrastructure and energy storage solutions while reducing the CO2 footprint of both suppliers and customers. Clean Energy Materials spans the vanadium, lithium, and tantalum value chains. AMG Critical Materials Technologies combines our leading vacuum furnace technology line with high-purity materials serving global leaders in the aerospace sector. AMG Critical Minerals consists of our mineral processing operations in antimony, graphite and silicon metal.

With approximately 3,000 employees, AMG operates globally with production facilities in Germany, the United Kingdom, France, the United States, China, Mexico, Brazil, India, Sri Lanka, and Mozambique, and has sales and customer service offices in Russia and Japan (www.amg-nv.com).

For further information, please contact:

AMG Advanced Metallurgical Group N.V.         +1 610 975 4979

Michele Fischer

[email protected]

Disclaimer

Certain statements in this press release are not historical facts and are “forward looking.”  Forward looking statements include statements concerning AMG’s plans, expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans and intentions relating to acquisitions, AMG’s competitive strengths and weaknesses, plans or goals relating to forecasted production, reserves, financial position and future operations and development, AMG’s business strategy and the trends AMG anticipates in the industries and the political and legal environment in which it operates and other information that is not historical information.  When used in this press release, the words “expects,” “believes,” “anticipates,” “plans,” “may,” “will,” “should,” and similar expressions, and the negatives thereof, are intended to identify forward looking statements.  By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that the predictions, forecasts, projections and other forward-looking statements will not be achieved.  These forward-looking statements speak only as of the date of this press release.  AMG expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained herein to reflect any change in AMG’s expectations with regard thereto or any change in events, conditions, or circumstances on which any forward-looking statement is based.

Attachment



Posted on

Xcel Energy Announces 2030 Clean Energy Plan to Reduce Carbon Emissions 85%

Xcel Energy Announces 2030 Clean Energy Plan to Reduce Carbon Emissions 85%

Plan to deliver 80% renewable energy while assuring an affordable, reliable energy system

DENVER–(BUSINESS WIRE)–
Xcel Energy – Colorado today announced the details of its upcoming Clean Energy Plan today that will deliver its customers an estimated 85% reduction in carbon dioxide emissions from 2005 levels by 2030. The plan will result in greater reductions than required by Colorado law and will double renewable energy and battery storage on the Xcel Energy Colorado system, providing customers with electricity derived from approximately 80% renewable sources while maintaining affordable and reliable energy service.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005742/en/

In 2018, Xcel Energy became the first utility in the nation to announce a vision of a carbon-free electricity system by 2050. This announcement continues not only the company’s vision to lead the clean energy transition, but also presents a balanced, diversified portfolio of energy sources to maintain reliability and affordability while supporting communities as we work together to meet Colorado’s carbon-reduction goals and evolving energy needs. Highlights of the plan include:

  • Adds approximately 5,500 MW of new wind, solar generation and battery storage;
  • Significantly reduces coal plant operations by 2030 and retires or repowers all remaining coal units by 2040;
  • Building upon successful customer focused energy-efficiency programs, distributed generation opportunities, and demand response options to manage energy load;
  • Ensuring grid stability and reliability with flexible resources capable of operating around renewable resources as well as during times of extreme heat or cold;
  • Creating a workforce and community transition plan, building upon the utility’s experience leading clean energy transitions across its service area; and
  • Evaluating transmission infrastructure in the state to improve the reliability and flexibility of the system and reduce the cost of the renewable energy additions contemplated by this plan.

Xcel Energy’s Colorado customers’ electricity bills are already among the lowest in the nation, and this balanced energy plan will continue to keep bills low. The plan is estimated to result in customer bill increases at or below the rate of inflation.

No layoffs are anticipated at any of the coal plants affected by the plan. Company and union leaders are partnering to manage this transition through attrition, retirement and retraining of employees.

The plan will go before the Colorado Public Utilities Commission late next month.

“We have a long track record of successfully transitioning our plants to meet future energy needs and look forward to doing so in Colorado, a state with leaders who share our clean energy goals,” said Ben Fowke, chairman and CEO, Xcel Energy. “We are committed to working with our employees and the communities we serve as we make significant strides leading the nation’s and Colorado’s ambitious clean energy transition, while also ensuring reliability and affordability for our customers.”

“Colorado is getting cleaner air, more good jobs, and savings for consumers with more renewable energy,” said Colorado Governor Jared Polis. “This proposal puts reliability and consumer savings as top priorities. This plan doubles wind and solar, advances my administration’s Greenhouse Gas Reduction roadmap and our bold goal of achieving 100% renewable energy by 2040.”

“We’re excited to lead the way in Colorado’s clean energy transformation and reduce carbon emissions approximately 85% by 2030,’’ said Alice Jackson, president of Xcel Energy – Colorado. “This ambitious agenda delivers clean, reliable, affordable energy for our Colorado customers and communities and brings us closer to our vision of delivering 100% carbon-free electricity to customers by 2050.”

“We have a tremendous labor force in the state that is dedicated to providing the power Coloradans need while maintaining a safe, reliable energy grid,” said Rich Meisinger, Business Manager of IBEW Local 111. ‘’We’re committed to keeping our members on the job whether they work for one of the utilities or they work for one of the electrical contractors we represent and look forward to demonstrating the value they can deliver in the future.”

“Many electric utilities have set goals that could put them on a path consistent with the science. Xcel Energy is actually changing their operations and aligning their investments to achieve those goals,” said Jon Goldin-Dubois, president, Western Resource Advocates. “What sets Xcel Energy apart is that they continue to be willing to work in partnership to realign their business to develop concrete plans to achieve the ambitious emissions reduction goals from electricity generation that are necessary to address climate change.”

“In our role as a consumer advocate, Energy Outreach Colorado is optimistic about the focus on equity, affordability and the health benefits in Xcel Energy’s Clean Energy Plan for the vulnerable Coloradans that we represent,” said Jennifer Gremmert, executive director, Energy Outreach Colorado. “Now more than ever, we understand the critical nature of affordable, reliable and accessible home energy to ensure that everyone can thrive.”

About Xcel Energy

Xcel Energy (NASDAQ: XEL) provides the energy that powers millions of homes and businesses across eight Western and Midwestern states. Headquartered in Minneapolis, the company is an industry leader in responsibly reducing carbon emissions and producing and delivering clean energy solutions from a variety of renewable sources at competitive prices. For more information, visit xcelenergy.com or follow us on Twitter and Facebook.

Xcel Energy Media Relations

(303) 294-2300

www.xcelenergy.com

KEYWORDS: Minnesota Colorado United States North America

INDUSTRY KEYWORDS: Other Energy Environment Utilities Coal Alternative Energy Energy

MEDIA:

Logo
Logo
Posted on

Antibe Therapeutics Announces Closing of Bought Deal Public Offering

Antibe Therapeutics Announces Closing of Bought Deal Public Offering

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES

TORONTO–(BUSINESS WIRE)–
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSX:ATE) today announced that it has closed its previously announced bought deal public offering of 6,727,500units (the “Offered Securities”) in the capital of the Company at a price of C$6.00per Offered Security (the “Offering Price”) for aggregate gross proceeds to the Company of C$40,365,000 (the “Offering”), which includes the full exercise of the over-allotment option by the underwriters.

Each Offered Security consisted of one common share (a “Common Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to acquire one Common Share at an exercise price per Common Share of C$7.50 for a period of 36 months from the closing of the Offering.

The Company intends to use the net proceeds of the Offering to fully fund the adaptive Phase III efficacy trial and remaining non-clinical studies for its lead drug, complete IND-enabling studies for its second and third pipeline drugs, advance new anti-inflammatory drug candidates and for working capital and general corporate purposes, all as more fully described in the prospectus. As of today’s date, the Company’s cash balance is C$74 million, including the upfront payment received from Nuance Pharma and the net proceeds of the Offering.

Canaccord Genuity Corp. acted as sole bookrunner and co-lead underwriter with Bloom Burton Securities Inc., on behalf of a syndicate of underwriters including Echelon Wealth Partners Inc., Leede Jones Gable Inc. and Paradigm Capital Inc. (together, the “Underwriters”).

The Offered Securities were offered in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario, pursuant to a prospectus supplement dated February 19, 2021 to the Company’s base shelf prospectus dated January 12, 2021 (the “Prospectus”) and elsewhere in compliance with applicable securities laws.

The securities offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, persons in the United States or “U.S. persons” (as such term is defined in Regulation S promulgated under the U.S. Securities Act) absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Antibe Therapeutics Inc.

Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. Antibe’s current pipeline includes three assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul (formerly ATB-346), is entering Phase III for osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-safe alternative to low-dose aspirin. The Company’s next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.

Forward Looking Information

This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar wording. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

Antibe Therapeutics Inc.

Christina Cameron

VP Investor Relations

+1 416-922-3460

[email protected]

Stern Investor Relations

Courtney Turiano

+1 212-362-1200

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Health Pharmaceutical

MEDIA:

Logo
Logo
Posted on

IIROC Trading Resumption – PGV

Canada NewsWire

VANCOUVER, BC, Feb. 24, 2021 /CNW/ – Trading resumes in:

Company: Prodigy Ventures Inc.

TSX-Venture Symbol: PGV

All Issues: Yes

Resumption (ET): 1:45 PM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Posted on

BLUE SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc.

NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) — Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline for investors to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE) from May 11, 2020 through November 4, 2020(the “Class Period”). The lawsuit filed in the United States District Court for the Eastern District of New York alleges violations of the Securities Exchange Act of 1934.

If you purchased bluebird securities, and/or would like to discuss your legal rights and options please visit BLUE Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected]

The complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose to investors: (i) data supporting bluebird’s BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (ii) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company’s BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On November 4, 2020, post-market, bluebird disclosed that it would no longer apply for FDA approval of its LentiGlobin product as a treatment for SCD in the second half of 2021 as expected. Instead, citing “feedback” from the FDA requiring the Company to provide additional data “to demonstrate drug product comparability” for LentiGlobin for SCD, “alongside COVID-19 related shifts and contract manufacturing organization COVID-19 impacts,” bluebird adjusted its submission timing to late 2022.

On this news, bluebird’s stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020.

If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased bluebird securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/bluebirdbioinc-blue-shareholder-class-action-lawsuit-stock-fraud-361/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected]

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
[email protected]



Posted on

S&P Global to Present at Raymond James & Associates’ 42nd Annual Institutional Investors Conference on March 1

Session will be Webcast

PR Newswire

NEW YORK, Feb. 24, 2021 /PRNewswire/ — Douglas L. Peterson, President and Chief Executive Officer of S&P Global (NYSE: SPGI), will present at the Raymond James & Associates’ virtual 42nd Annual Institutional Investors Conference on March 1, 2021. Mr. Peterson is scheduled to speak from 2:10 p.m. to 2:50 p.m. Eastern Time. The “fireside chat” will be webcast and may include forward-looking information.

Webcast Instructions:  Live and Replay
The video webcast will be available live and in replay through the Company’s Investor Relations website http://investor.spglobal.com/Investor-Presentations (please copy and paste URL into web browser). The webcast replay will be available approximately one hour after the end of the presentation and will remain accessible for one year. An accompanying slide presentation will also be posted and available for download. Any additional information presented during the presentation will be made available on the Company’s Investor Presentations web page.

About S&P Global
S&P Global (NYSE: SPGI) is the world’s foremost provider of credit ratings, benchmarks and analytics in the global capital and commodity markets, offering ESG solutions, deep data and insights on critical business factors.  We’ve been providing essential intelligence that unlocks opportunity, fosters growth and accelerates progress for more than 160 years. Our divisions include S&P Global Ratings, S&P Global Market Intelligence, S&P Dow Jones Indices and S&P Global Platts. For more information, visit www.spglobal.com.

Investor Relations:  http://investor.spglobal.com

Get news direct via RSS:
http://investor.spglobal.com/RSS-Feeds/Index?keyGenPage=1073751617

Contact:

Investor Relations:

Chip Merritt

Senior Vice President, Investor Relations
(212) 438-4321 (office)
[email protected]

News Media:

Christopher Krantz

Lead, Communications
+44 20 7176 0060
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/sp-global-to-present-at-raymond-james–associates-42nd-annual-institutional-investors-conference-on-march-1-301234866.html

SOURCE S&P Global

Posted on

Textron Declares Quarterly Dividend

Textron Declares Quarterly Dividend

PROVIDENCE, R.I.–(BUSINESS WIRE)–
The Board of Directors of Textron Inc. (NYSE:TXT) today declared a quarterly dividend of $0.02 per share on the company’s Common Stock.

All dividends will be paid on April 1, 2021 to holders of record at the close of business on March 12, 2021.

About Textron Inc.

Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Hawker, Jacobsen, Kautex, Lycoming, E-Z-GO, Arctic Cat, Textron Systems, and TRU Simulation + Training. For more information visit: www.textron.com.

Investor Contacts:

Eric Salander – 401-457-2288

Cameron Vollmuth – 401-457-2288

Media Contact:

Michael Maynard – 401-457-2362

KEYWORDS: Rhode Island United States North America

INDUSTRY KEYWORDS: Other Defense Other Energy Professional Services Energy Defense Other Manufacturing Insurance Chemicals/Plastics Automotive Manufacturing Finance Aerospace Manufacturing

MEDIA:

Logo
Logo
Posted on

Arcadia Biosciences Welcomes Debbie Carosella to Board Of Directors

— Prominent leader in consumer food industry will help guide commercialization strategy for innovative health and nutrition ingredients —

PR Newswire

DAVIS, Calif., Feb. 24, 2021 /PRNewswire/ — Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, announced today that Debbie Carosella, a leading consumer food industry executive, has joined its board of directors.

Carosella is the former CEO of Madhava Natural Sweeteners, a company that provides natural alternatives to refined sugars and artificial sweeteners. A recognized leader in the natural and organic food industry, she previously served as the senior vice president of innovation for Dean Foods/ WhiteWave Foods where she led the development of value-added brands across the company. Prior to that, Carosella was on the executive leadership team at ConAgra Foods where she was both a general manager and innovator for numerous brands in a multitude of food categories.

“Debbie is a proven leader in driving innovation and growth for consumer packaged goods companies,” said Kevin Comcowich, chair of Arcadia’s board of directors. “With her broad expertise in business strategy, consumer marketing and brand development, she will be a valuable addition to the board as we execute our commercial strategy for GoodWheat™ and GoodHemp™ nutrition and health products.”

“It is exciting to be associated with a science-based company like Arcadia that has unlocked meaningfully differentiated food benefits,” said Carosella. “I look forward to working with the company to help bring these products to food companies and consumers.”

Carosella is a graduate of the University of Missouri, where she earned a bachelor’s degree in journalism. She currently advises multiple natural and organic companies on a broad range of business initiatives and serves on numerous corporate and non-profit boards.

About Arcadia Biosciences
Arcadia Biosciences (Nasdaq: RKDA) is a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients. The company’s GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. Arcadia’s GoodHemp™ seed catalog delivers genetically superior hemp seeds, transplants and extracts, applying the company’s proprietary crop innovation technology, ArcaTech™, to an emerging crop. For more information, visit www.arcadiabio.com.

Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the demand for the company’s products, both from commercial partners and consumers; the company’s and its partners’ ability to develop commercial products incorporating its traits and complete the regulatory review process for such products; the company’s compliance with laws and regulations that impact the company’s business, and changes to such laws and regulations; the company’s future capital requirements and ability to satisfy its capital needs; and the other risks set forth in the company’s filings with the Securities and Exchange Commission from time to time, including the risks set forth in the company’s annual report on Form 10-K for the year ended December 31, 2019 and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.

LinkedIn: Arcadia Biosciences 
Twitter: @ArcadiaAg

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/arcadia-biosciences-welcomes-debbie-carosella-to-board-of-directors-301234864.html

SOURCE Arcadia Biosciences

Posted on

Canada Carbon Inc.: CPTAQ Meeting Date Set

MISSISSAUGA, Ontario, Feb. 24, 2021 (GLOBE NEWSWIRE) — Canada Carbon Inc. (the “Company” or “Canada Carbon”) (TSX-V:CCB), (FF:U7N1) has been informed that the Commission de protection du territoire agricole du Québec (“CPTAQ”) has set the dates of the public meeting to review the positive preliminary orientation on Canada Carbon’s Miller Project file as March 31, 2021 and April 1, 2021. The first day of the meetings will be dedicated to presentations by legal representatives of the interested parties. The second day will be dedicated to public comments and presentations.

For further information:

Olga Nikitovic
Interim CEO
Canada Carbon Inc.
[email protected]

Valerie Pomerleau
Director Public Affairs and Communications
Canada Carbon Inc.
[email protected]
(819) 856-5678

“Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”

FORWARD LOOKING STATEMENTS: This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR in Canada (available at www.sedar.com).